Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blockers and hypertension.

W Flamenbaum1

  • 1Department of Medicine, Mt. Sinai School of Medicine, New York, New York.

American Journal of Hypertension
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Selecting antihypertensive agents requires considering organ function. Some beta-blockers, like propranolol, can impair renal function, while others, such as labetalol, preserve it.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers.

Journal of clinical pharmacology·1996
Same author

Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension.

Journal of human hypertension·1994
Same author

Comparison of the efficacy and tolerability of an angiotensin converting enzyme inhibitor (lisinopril) versus a calcium channel antagonist (diltiazem SR) in the treatment of moderate to severe hypertension.

Journal of human hypertension·1994
Same author

Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group.

Archives of neurology·1992
Same author

Effect of lovastatin on serum lipids in patients with nonfamilial primary hypercholesterolemia.

Clinical therapeutics·1989
Same author

Hypertension, changes in high-density lipoproteins and antihypertensive therapy.

The American journal of cardiology·1989
Same journal

ADAM17 as a promising molecular target for organ protection in antihypertensive therapy.

American journal of hypertension·2026
Same journal

Efficacy and Safety of Baxdrostat in the Management of Uncontrolled Hypertension: A Systematic Review and Meta-Analysis.

American journal of hypertension·2026
Same journal

Hemodynamic Evolution of Heart Failure from Hypertension: Lower Stroke Volume Index and Higher Heart Rate.

American journal of hypertension·2026
Same journal

Opposite Seasonal Variation in Nighttime and Morning Blood Pressure: A Longitudinal Study of Patients with Hypertension.

American journal of hypertension·2026
Same journal

Screening for Postprandial Hypotension: The Importance of Home Blood Pressure Monitoring.

American journal of hypertension·2026
Same journal

Distinct Mediating Roles of Hypertension in Arterial Stiffness Mechanisms Associated with Cardiovascular Disease Risk: A Community-Based Cohort Study.

American journal of hypertension·2026
See all related articles

Area of Science:

  • Cardiovascular Pharmacology
  • Nephrology
  • Hypertension Management

Background:

  • Controversy exists in selecting antihypertensive agents beyond side effects.
  • The impact of antihypertensive drugs on core organ function is a critical selection factor.
  • Propranolol, an early beta-blocker, may decrease blood pressure at the expense of cardiac function and renal blood flow (RBF) and glomerular filtration rate (GFR).

Purpose of the Study:

  • To evaluate the effects of different beta-adrenergic receptor blocking agents on renal function in hypertension.
  • To compare the renal effects of non-cardioselective beta-blockers with and without intrinsic sympathomimetic activity.
  • To assess the impact of combined alpha- and beta-blockade on renal function during hypertension treatment.

Main Methods:

Related Experiment Videos

  • Review of existing literature on beta-adrenoceptor-blocking agents and their effects on blood pressure, cardiac function, and renal parameters (GFR and RBF).
  • Comparison of the effects of propranolol, cardioselective beta-blockers, nadolol, and labetalol on renal function.
  • Analysis of mechanisms by which different beta-blockers influence vasomotor tone and cardiac output.

Main Results:

  • Propranolol therapy may lead to decreased GFR and RBF.
  • Nadolol, a non-cardioselective beta-blocker, unexpectedly preserved or improved RBF and GFR.
  • Labetalol, combining beta-blockade with alpha-adrenoceptor blockade, preserves GFR and RBF in hypertensive patients.

Conclusions:

  • The choice of antihypertensive agent significantly impacts renal function.
  • Beta-blockers with combined alpha- and beta-blockade (e.g., labetalol) offer advantages in preserving renal function.
  • Further research into the mechanisms of renal protection by specific antihypertensive agents is warranted.